Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Causation and Risk

From General Health Science to Targeted Risk Assessment

For decades, the public health landscape has been shaped by broad, accessible information on general wellness and disease prevention. This legacy of general health science communication has empowered individuals to make informed lifestyle choices, from nutrition to routine screenings. Within this framework, cancer risk has often been discussed in terms of behavioral or environmental factors, such as smoking or sun exposure. However, as medical science advances, the focus has increasingly shifted toward specific therapeutic agents and their potential long-term consequences. This transition is particularly evident in the domain of oncology, where novel immunotherapies have revolutionized treatment paradigms. One such agent, Avelumab, a PD-L1 inhibitor approved for Merkel Cell Carcinoma, has prompted rigorous investigation into its risk profile. The question now moves beyond general health advice to a more targeted occupational concern: for healthcare workers, pharmacists, and researchers who handle or administer Avelumab, what does the emerging evidence suggest about exposure-related risks? This pivot from population-level health guidance to workplace-specific hazard assessment requires a careful examination of available pharmacokinetic and toxicological data, without venturing into unsubstantiated mechanistic claims.

Understanding Avelumab: Mechanism and Approved Use

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for use in this indication, and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Disease Characteristics and Risk Factors

Merkel cell carcinoma is a rare, highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381/). Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and MCC is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors (ICIs) offer durable responses and significant clinical benefit, with two agents—avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1)—currently approved by the U.S. Food and Drug Administration for the treatment of advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). The standard treatment of metastatic MCC is the use of anti-PD-1/-PD-L1 immune checkpoint inhibitors such as pembrolizumab or avelumab, which in comparison with conventional chemotherapy show better overall response rates and longer duration of responses in patients (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Avelumab as a Treatment, Not a Cause: Evidence from Clinical Studies

Mechanistic pathways linking avelumab to Merkel cell carcinoma are primarily therapeutic rather than causative. Avelumab is used to treat MCC by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells. However, in the context of causation, the evidence does not indicate that avelumab causes MCC. Instead, avelumab is a treatment for MCC, and the risk narrative centers on its efficacy and the potential for adverse effects or lack of response. For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a study of five patients with metastatic MCC refractory to avelumab who were later treated with combined ipilimumab and nivolumab, three out of five responded according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further underscores that despite advances, about 50% of patients progress on ICI therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Risk Context: Treatment Failure and Immune-Related Adverse Events

Nevertheless, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop ICI-induced, immune-related adverse events (irAEs), due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). Regarding adequacy of warnings, the evidence does not directly address labeling or risk communication. However, the approved indication for avelumab in metastatic MCC implies that warnings would focus on its use as a treatment, not as a cause of the disease. Causation-related considerations for affected patients are therefore not about avelumab causing MCC, but about the risks of treatment failure or immune-related adverse events. The timeline between exposure and documented harm is relevant to treatment response: patients may experience progression or adverse events during or after avelumab therapy. The JAVELIN Merkel 200 trial provided data on response rates, but specific timelines for harm are not detailed in the provided evidence. In summary, the evidence consistently positions avelumab as a therapeutic agent for MCC, not a causative factor. The risk narrative involves treatment efficacy, refractoriness, and immune-related adverse events. No evidence suggests a causal link between avelumab exposure and the development of MCC. Instead, avelumab is used to manage an existing diagnosis of MCC, with variable response rates and potential for progression.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence does not indicate that avelumab causes Merkel cell carcinoma. Avelumab is a therapeutic agent used to treat MCC by blocking PD-L1 and enhancing the immune response against cancer cells. The risk narrative centers on its efficacy and potential adverse effects, not causation.

What are the main risks associated with avelumab treatment for MCC?

The main risks include treatment failure (approximately 50% of patients progress on therapy) and immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

What is the evidence for avelumab's efficacy in MCC?

The JAVELIN Merkel 200 trial showed confirmed objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Response rates to PD-1/PD-L1 inhibition can reach up to 62% in some studies (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.